Watching Apellis Pharmaceuticals; Traders Circulate Comments From Jefferies Suggesting The FDA Has Put Out A FAERS Update Which Included A New Additional Death On Syfovre; Says "Does Not Change Our View On Syfovre's Safety"
Portfolio Pulse from Benzinga Newsdesk
Traders are closely monitoring Apellis Pharmaceuticals after Jefferies circulated comments about an FDA FAERS update that included a new death related to Syfovre. Jefferies maintains that this does not change their view on Syfovre's safety.
July 31, 2024 | 2:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Apellis Pharmaceuticals is under scrutiny after an FDA FAERS update included a new death related to Syfovre. Jefferies, however, maintains their view on the drug's safety.
The mention of a new death related to Syfovre in the FDA FAERS update is likely to cause concern among investors, potentially leading to a short-term decline in Apellis Pharmaceuticals' stock price. However, Jefferies' stance that this does not change their view on the drug's safety may mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100